Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Dr Desai argued that the sector is undergoing a structural acceleration in how quickly science turns into treatments
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
Subscribe To Our Newsletter & Stay Updated
